As of 2025-04-21, the Intrinsic Value of Inhibrx Inc (INBX) is 877.89 USD. This INBX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 11.47 USD, the upside of Inhibrx Inc is 7,553.80%.
The range of the Intrinsic Value is 632.83 - 1,494.18 USD
Based on its market price of 11.47 USD and our intrinsic valuation, Inhibrx Inc (INBX) is undervalued by 7,553.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 632.83 - 1,494.18 | 877.89 | 7553.8% |
| DCF (Growth 10y) | 681.22 - 1,595.08 | 943.11 | 8122.4% |
| DCF (EBITDA 5y) | 917.83 - 1,437.79 | 1,130.72 | 9758.0% |
| DCF (EBITDA 10y) | 835.42 - 1,550.20 | 1,108.56 | 9564.9% |
| Fair Value | 2,913.63 - 2,913.63 | 2,913.63 | 25,302.14% |
| P/E | 1,465.10 - 3,729.44 | 2,437.02 | 21146.9% |
| EV/EBITDA | (194.01) - 3,715.37 | 1,100.38 | 9493.5% |
| EPV | (60.36) - (143.30) | (101.83) | -987.8% |
| DDM - Stable | 610.46 - 1,141.31 | 875.89 | 7536.4% |
| DDM - Multi | 467.19 - 717.47 | 568.70 | 4858.1% |
| Market Cap (mil) | 166.09 |
| Beta | 0.38 |
| Outstanding shares (mil) | 14.48 |
| Enterprise Value (mil) | 13.49 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.78% |
| Cost of Debt | 15.99% |
| WACC | 11.73% |